Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features

APOBEC3A hairpin passenger hotspots Genomic features are often examined at extremes to determine the impact of mutations. These genomic regions span from the trinucleotide context to megabases that underlie chromatin and chromosomal features. Examining mutational dynamics at the mesoscale, the intermediate span of the genome, Buisson et al. characterized the mutational dynamics of cancer (see the Perspective by Carter). They found that mutations caused by the APOBEC enzyme in DNA stem-loops, a mesoscale feature of the genome, could drive recurrent mutations. Many of these types of mutations have been identified as likely drivers of cancer. However, APOBEC-generated mutations outside of stem-loops were more likely to be cancer driver mutations, providing a genomic context for separating cancer driver from passenger mutations. Science, this issue p. eaaw2872; see also p. 1228 An analysis of more than 2500 human tumors reveals that cancer driver and passenger mutations can be identified from mesoscale genomic context. INTRODUCTION Extensive tumor sequencing efforts have transformed the way in which cancer driver genes are identified. Appropriate statistical modeling is crucial for distinguishing true drivers from passenger events that accumulate during tumorigenesis but provide no fitness advantage to cancer cells. A central assumption used in discovering driver genes and specific driver mutations is that exact positional recurrence is unlikely by chance: Seeing exactly the same DNA base pair mutated recurrently across patients is taken as proof that the mutation must be under functional selection for contributing to tumor fitness. The assumption is that mutational processes, being essentially random, are unlikely to hit the exact same base pair over and over again. However, although functional selection is clearly a key cause of recurrent mutations in cancers, whether it is the only prominent cause is not known. RATIONALE To distinguish driver mutations from passengers, it is critical to understand the landscape of background mutations in cancer genomes. Recent pan-cancer mutation analyses have revealed rules of mutation distribution at the smallest (one to three base pairs) and largest (megabase) scales. At the small scale, mutational processes such as those attributable to sunlight, cigarette smoke, or random DNA copying errors generate patterns known as mutational signatures at the trinucleotide level. At the opposite extreme, the cell’s nucleus is organized into two large compartments known as A and B, each consisting of multi-megabase chromatin domains. Compartment A contains gene-rich, open, active, early-replicating euchromatin. Compartment B contains gene-poor, closed, inactive, and late-replicating heterochromatin. Mutation frequency is generally higher in compartment B. Cancer genomes have been studied in detail at these two opposite scales, but less attention has been paid so far to the intervening “mesoscale.” RESULTS We investigated the influence of mesoscale genomic features on mutational recurrence. We found that mutagenesis by the cytidine deaminase APOBEC3A is uniquely sensitive to mesoscale features, specifically the ability of DNA to adopt particular “hairpin” (stem-loop) structures while transiently single-stranded. Identifying DNA loci that can form hairpins requires sequence analysis at the mesoscale (~30–base pair) level. Combining biochemistry and bioinformatics, we deduced the features of APOBEC3A’s optimal DNA substrates, revealing that cytosine bases presented in a short loop at the end of a strongly paired stem can be mutated up to 200 times as frequently as nonhairpin sites. Analyzing the most frequent APOBEC mutations in protein-coding regions of cancer genomes, we identified numerous recurrent mutations at optimal hairpins in genes unconnected to cancer. Conversely, we found that mutational hotspots at nonoptimal sites are enriched in known cancer driver genes. CONCLUSION Our results indicate that there are multiple possible routes to mutational hotspots in cancer. Functional mutations in oncogenes or tumor suppressors can rise to prominence through positive selection. These driver hotspots are not restricted to the “favorite” sites of any particular mutagen. In contrast, DNA sites that happen to be perfect substrates for a mutagen can give rise to “passenger hotspot mutations” that owe their prevalence to substrate optimality, not to any effects on tumor fitness. In light of these findings, we recommend caution in interpreting the long lists of putative novel cancer driver hotspots being produced by high-throughput sequencing projects. APOBEC3A has a taste for hairpins. The APOBEC cytidine deaminase enzymes are a prominent cause of mutations in cancer. Analysis of mutational patterns at the mesoscale (~30–base pair) level reveals that APOBEC3A strongly prefers “hairpin” substrates. These stem-loop DNA structures can form via intrastrand base pairing. Cytosine bases presented at the end of a stable hairpin are exceptionally vulnerable to attack by APOBEC3A, leading to recurrent mutations in the absence of any selective benefit (“passenger hotspots,” left). In contrast, APOBEC mutational hotspots in known cancer driver genes (“driver hotspots,” right) are not restricted to any particular kind of DNA structure. Cancer drivers require statistical modeling to distinguish them from passenger events, which accumulate during tumorigenesis but provide no fitness advantage to cancer cells. The discovery of driver genes and mutations relies on the assumption that exact positional recurrence is unlikely by chance; thus, the precise sharing of mutations across patients identifies drivers. Examining the mutation landscape in cancer genomes, we found that many recurrent cancer mutations previously designated as drivers are likely passengers. Our integrated bioinformatic and biochemical analyses revealed that these passenger hotspot mutations arise from the preference of APOBEC3A, a cytidine deaminase, for DNA stem-loops. Conversely, recurrent APOBEC-signature mutations not in stem-loops are enriched in well-characterized driver genes and may predict new drivers. This demonstrates that mesoscale genomic features need to be integrated into computational models aimed at identifying mutations linked to diseases.

[1]  P. Lønning,et al.  APOBEC3A/B deletion polymorphism and cancer risk , 2017, Carcinogenesis.

[2]  N. A. Temiz,et al.  APOBEC3B is an enzymatic source of mutation in breast cancer , 2013, Nature.

[3]  Julian M. Hess,et al.  Passenger Hotspot Mutations in Cancer , 2019, bioRxiv.

[4]  M. Weitzman,et al.  APOBEC3A can activate the DNA damage response and cause cell‐cycle arrest , 2011, EMBO reports.

[5]  I. Amit,et al.  Comprehensive mapping of long range interactions reveals folding principles of the human genome , 2011 .

[6]  Jason B. Nikas,et al.  APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. , 2013, Cancer research.

[7]  Li Ding,et al.  Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. , 2018, Cell systems.

[8]  C. Schiffer,et al.  Substrate sequence selectivity of APOBEC3A implicates intra-DNA interactions , 2017, Scientific Reports.

[9]  A. Eyre-Walker,et al.  How Much of the Variation in the Mutation Rate Along the Human Genome Can Be Explained? , 2014, G3: Genes, Genomes, Genetics.

[10]  Chandra Sekhar Pedamallu,et al.  Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas , 2016, Nature Genetics.

[11]  P. Mieczkowski,et al.  APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication. , 2016, Cell reports.

[12]  Alan Hodgkinson,et al.  Variation in the mutation rate across mammalian genomes , 2011, Nature Reviews Genetics.

[13]  S. Antonarakis,et al.  APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication , 2016, Genome research.

[14]  N. A. Temiz,et al.  Evidence for APOBEC3B mutagenesis in multiple human cancers , 2013, Nature Genetics.

[15]  Chiraag D. Kapadia,et al.  Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation , 2017, eLife.

[16]  Radhakrishnan Sabarinathan,et al.  Nucleotide excision repair is impaired by binding of transcription factors to DNA , 2015, Nature.

[17]  S. Wain-Hobson,et al.  Molecular basis of the attenuated phenotype of human APOBEC3B DNA mutator enzyme , 2015, Nucleic acids research.

[18]  Alan Hodgkinson,et al.  Cryptic Variation in the Human Mutation Rate , 2009, PLoS biology.

[19]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[20]  Gad Getz,et al.  An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers , 2015, Nature Genetics.

[21]  M. Stenglein,et al.  APOBEC3 proteins mediate the clearance of foreign DNA from human cells , 2010, Nature Structural &Molecular Biology.

[22]  N. Socci,et al.  Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity , 2015, Nature Biotechnology.

[23]  M. Malim,et al.  Defining APOBEC3 Expression Patterns in Human Tissues and Hematopoietic Cell Subsets , 2009, Journal of Virology.

[24]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[25]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[26]  J. SantaLucia,et al.  A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. McKenna,et al.  Exome and whole genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity , 2013, Nature Genetics.

[28]  Sandro Morganella,et al.  Noncanonical secondary structures arising from non-B DNA motifs are determinants of mutagenesis. , 2018, Genome research.

[29]  J. Mazières,et al.  The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism , 2016, EMBO molecular medicine.

[30]  Rommie E. Amaro,et al.  Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B , 2016, Nature Structural &Molecular Biology.

[31]  Steven A. Roberts,et al.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.

[32]  Nuria Lopez-Bigas,et al.  Somatic and Germline Mutation Periodicity Follow the Orientation of the DNA Minor Groove around Nucleosomes , 2018, Cell.

[33]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[34]  M. Carpenter,et al.  The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis , 2016, Nature Communications.

[35]  Lela Lackey,et al.  Endogenous APOBEC3A DNA Cytosine Deaminase Is Cytoplasmic and Nongenotoxic* , 2013, The Journal of Biological Chemistry.

[36]  Jesse R. Dixon,et al.  Chromatin Domains: The Unit of Chromosome Organization. , 2016, Molecular cell.

[37]  M. McElrath,et al.  Innate Immune Signaling Induces High Levels of TC-specific Deaminase Activity in Primary Monocyte-derived Cells through Expression of APOBEC3A Isoforms* , 2010, The Journal of Biological Chemistry.

[38]  U. Manne,et al.  Prognostic and Predictive Biomarkers for Colorectal Cancer , 2017 .

[39]  J. Stamatoyannopoulos,et al.  Human mutation rate associated with DNA replication timing , 2009, Nature Genetics.

[40]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[41]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[42]  J. A. Halliday,et al.  Engineered proteins detect spontaneous DNA breakage in human and bacterial cells , 2013, eLife.

[43]  J. Bischerour,et al.  Base-flipping dynamics in a DNA hairpin processing reaction , 2007, Nucleic acids research.

[44]  E. Lander,et al.  A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.

[45]  P. Xue,et al.  The Aryl Hydrocarbon Receptor and Tumor Immunity , 2018, Front. Immunol..

[46]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[47]  P. Hanawalt,et al.  Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair , 2016, Cell.

[48]  M. Stratton,et al.  Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis , 2019, Cell.

[49]  Alan Hodgkinson,et al.  The Genomic Distribution and Local Context of Coincident SNPs in Human and Chimpanzee , 2010, Genome biology and evolution.

[50]  C. Cole,et al.  The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers , 2018, Nature Reviews Cancer.

[51]  Yan Zhou,et al.  Synergistic role of Cul1 and c-Myc: Prognostic and predictive biomarkers in colorectal cancer. , 2017, Oncology reports.

[52]  Shraddha Sharma,et al.  Stem-loop structure preference for site-specific RNA editing by APOBEC3A and APOBEC3G , 2017, PeerJ.

[53]  Trevor J Pugh,et al.  Recurrent and functional regulatory mutations in breast cancer , 2017, Nature.

[54]  C. Schiffer,et al.  Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity , 2017, Nature Communications.

[55]  Laurent Farinelli,et al.  Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes. , 2010, Genome research.

[56]  M. Stratton,et al.  Short inverted repeats contribute to localized mutability in human somatic cells , 2017, Nucleic acids research.

[57]  Qi Zhang,et al.  KLF5 promotes cervical cancer proliferation, migration and invasion in a manner partly dependent on TNFRSF11a expression , 2017, Scientific Reports.